The plasma fractionation market focuses on separating human plasma into its essential components—such as immunoglobulins, albumin, coagulation factors, and other plasma-derived proteins—used to treat a wide range of conditions, including immune deficiencies, hemophilia, liver diseases, and neurological disorders. Plasma fractionation ensures the safe and efficient utilization of donated plasma for life-saving therapies. Market growth is driven by the rising prevalence of chronic and rare diseases, growing demand for immunoglobulin therapies, and advancements in plasma collection and purification technologies. Increasing awareness about plasma-derived treatments and expanding healthcare access in emerging markets are also contributing to market expansion.
The global plasma fractionation market size was valued at USD 37.31 billion in 2024 and is projected to grow from USD 40.27 billion in 2025 to USD 72.45 billion by 2032, exhibiting a strong CAGR of 8.75% during the forecast period. This growth is primarily driven by the increasing demand for plasma-derived therapies used in treating rare and chronic diseases such as hemophilia, immunodeficiency disorders, and liver diseases.
North America dominated the plasma fractionation market in 2024 with a market share of 56.18%, owing to its well-established healthcare infrastructure, advanced plasma collection systems, and strong presence of key industry players.